$CDMO News
Last published 1y ago
- 1y agoCDMOAvid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor ExperienceGlobeNewswireTUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 1y agoCDMOAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed MergerGlobeNewswireTUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by
- 1y agoCDMOAvid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital PartnersGlobeNewswireAcquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including
- 1y agoCDMOAvid Stockholders Approve Transaction with GHO and AmpersandGlobeNewswireTUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve
- 1y agoCDMOAvid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and AmpersandGlobeNewswireTUSTIN, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve
- 1y agoCDMOAvid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and AmpersandGlobeNewswireTUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve
- 1y agoCDMOAvid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and AmpersandGlobeNewswireTUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve
- 1y agoCDMOAvid Bioservices Recommends Stockholders Vote FOR Value Maximizing TransactionGlobeNewswireTUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve
- 1y agoCDMOAvid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024GlobeNewswireTUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 1y agoBRKHCDMOCTVEMKRKuehn Law Encourages BRKH, CDMO, EMKR, and CTV Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoAEALTRAVAVCDMOKuehn Law Encourages AVAV, AE, CDMO, and ALTR Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoCDMOCDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital PartnersGlobeNewswireMONSEY, New York, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Avid Bioservices (NASDAQ:CDMO) ("Avid") to GHO Capital Partners ("GHO")
- 2y agoCDMOAvid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion TransactionGlobeNewswireTUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO")
- 2y agoCDMOAvid Bioservices to Participate in Craig-Hallum Bioprocessing ConferenceGlobeNewswireTUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 2y agoCDMOAvid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCDMOAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024GlobeNewswire-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168
- 2y agoCDMOAvid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024GlobeNewswireTUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 2y agoCDMOAvid Bioservices, Inc. (CDMO) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCDMOAvid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024GlobeNewswire-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy
- 2y agoCDMOAvid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024GlobeNewswireTUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 2y agoCDMOAvid Bioservices Earns Committed Badge from EcoVadis for Sustainability PerformanceGlobeNewswireTUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high
- 2y agoCDMOAvid Bioservices to Participate at Upcoming Investor ConferencesGlobeNewswireTUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high
- 2y agoCDMOAvid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCDMOAvid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024GlobeNewswire-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion Program with Grand
- 2y agoCDMOAvid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-QGlobeNewswireTUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the
- 2y agoCDMOAvid Bioservices Announces Pricing of Private Placement of Convertible NotesGlobeNewswireTUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million
- 2y agoCDMOAvid Bioservices Announces Proposed Private Placement of Convertible NotesGlobeNewswireTUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer,
- 2y agoCDMOAvid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024GlobeNewswireTUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 2y agoCDMOAvid Bioservices, Inc. (CDMO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCDMOAvid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023GlobeNewswire-- Recorded Second Quarter Revenue of $25.4 Million -- -- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million -- -- Entered into Partnership with California Institute of Regenerative
- 2y agoCDMOAvid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023GlobeNewswireTUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoCDMOAvid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) ProgramsGlobeNewswireTUSTIN, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoCDMOAvid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing FacilityGlobeNewswireNewly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024 Completion of CGT Facility Brings Company's Total Revenue
- 3y agoCDMOAvid Bioservices to Participate in RBC Capital Markets Virtual CDMO ConferenceGlobeNewswireTUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoHPPCDMOPLKR+5Stocks making the biggest moves midday: Kroger, DocuSign, Planet Labs, First Solar and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y agoCDMOAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023GlobeNewswire-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains on Schedule for
- 3y agoCDMOAvid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023GlobeNewswireTUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoCDMOAvid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023GlobeNewswire-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a Record-High Backlog
- 3y agoCDMOAvid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023GlobeNewswireTUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoCDMOAvid Bioservices to Participate in RBC Capital Markets Global Healthcare ConferenceGlobeNewswireTUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high
- 3y agoCDMOAvid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future CustomersGlobeNewswireCompany to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility First Customer Project in Newly Expanded Capacity to Kick-Off This Month Company Also
- 3y agoCDMOAvid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent DevelopmentsGlobeNewswire-- Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter -- -- Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an Increase of 26%
- 3y agoCDMOAvid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023GlobeNewswireTUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoCDMOAvid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent DevelopmentsGlobeNewswire-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian Cell Facilities and
- 3y agoCDMOAvid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022GlobeNewswireTUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 3y agoCDMOAvid Bioservices Appoints Oksana Lukash as Vice President, PeopleGlobeNewswireTUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 4y agoCDMOAvid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare ConferenceGlobeNewswireTUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing
- 4y agoCDMOTOMZTOMI to Install Custom Engineered Integrated iHP System in Avid Bioservices, Inc. Viral Vector Manufacturing Facility in CaliforniaGlobeNewswireFREDERICK, Md/, Oct. 10, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary
- 4y agoCDMOCDMOPAvid Bioservices to Participate in RBC Global CDMO ConferenceGlobeNewswireTUSTIN, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa
- 4y agoCDMOCDMOPAvid Bioservices Appoints Michael Alston, Jr. as Vice President, OperationsGlobeNewswireTUSTIN, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa